Biotech News
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month Announced preliminary details for Phase 2 STORYLINE™ trial of ABS-201 for endometriosis Appointed former Galderma executive Gerry Muhle as Chief Commercial Officer
